Product Information
BREO ELLIPTA 100-25 MCG INHALR is a brand product labeled by GlaxoSmithKline LLC, priced at $5.3594 per EA under NDC 00173085914. Its NADAC has been published 642 times since Apr 23, 2014.
FDA first approved this application on May 10, 2013.
Strength
100; 25 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173085914
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
FLUTICASONE FUROATE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA204275FDA Approved
5/10/2013
On Market Since
8/26/2013
Pharmacological Classes
Price Statistics
The NADAC for BREO ELLIPTA 100-25 MCG INHALR has been published 642 times since Apr 23, 2014, and over the history we have for it it has risen 51.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.3594 per EA |
|---|---|
| All-time high | $5.3987 (May 15, 2024) |
| All-time low | $3.5340 (Apr 23, 2014) |
| 52-week high | $5.3785 |
| 52-week low | $5.3570 |
| Median price | $4.7946 |
| Average price | $4.6886 |
| Largest weekly change | +8.0% (Jan 11, 2017) |
| Weeks tracked | 642 |
| Tracking since | Apr 23, 2014 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BREO ELLIPTA 100-25 MCG INHALR?
The current National Average Drug Acquisition Cost (NADAC) for BREO ELLIPTA 100-25 MCG INHALR, manufactured by GlaxoSmithKline LLC, is $5.3594 per EA (NDC 00173085914), effective Aug 19, 2026.
How has the price of BREO ELLIPTA 100-25 MCG INHALR changed over time?
Over the history we have for it, the NADAC for BREO ELLIPTA 100-25 MCG INHALR has risen 51.6%. It has been tracked across 642 weekly CMS publications since Apr 23, 2014.
What are the highest and lowest recorded NADAC prices for BREO ELLIPTA 100-25 MCG INHALR?
Since Apr 23, 2014, the NADAC for BREO ELLIPTA 100-25 MCG INHALR has ranged from a low of $3.5340 (Apr 23, 2014) to a high of $5.3987 (May 15, 2024), with a median of $4.7946 per EA.
Are there cheaper alternatives to BREO ELLIPTA 100-25 MCG INHALR?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BREO ELLIPTA 100-25 MCG INHALR in a comparable dosage form, but none are currently priced below it.
Who manufactures BREO ELLIPTA 100-25 MCG INHALR?
BREO ELLIPTA 100-25 MCG INHALR (NDC 00173085914) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.